Cladis Investment Advisory LLC Has $885,000 Position in CVS Health Co. (NYSE:CVS)

Cladis Investment Advisory LLC decreased its holdings in shares of CVS Health Co. (NYSE:CVS) by 24.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,069 shares of the pharmacy operator’s stock after selling 4,523 shares during the period. Cladis Investment Advisory LLC’s holdings in CVS Health were worth $885,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of CVS. Park Place Capital Corp boosted its stake in CVS Health by 18.1% in the second quarter. Park Place Capital Corp now owns 2,033 shares of the pharmacy operator’s stock worth $120,000 after purchasing an additional 311 shares in the last quarter. GAMMA Investing LLC grew its holdings in CVS Health by 7.5% during the 2nd quarter. GAMMA Investing LLC now owns 9,032 shares of the pharmacy operator’s stock worth $533,000 after acquiring an additional 628 shares during the last quarter. Mather Group LLC. raised its stake in shares of CVS Health by 43.5% in the second quarter. Mather Group LLC. now owns 11,588 shares of the pharmacy operator’s stock worth $684,000 after acquiring an additional 3,512 shares during the last quarter. Lynx Investment Advisory acquired a new position in shares of CVS Health during the second quarter worth approximately $203,000. Finally, Value Partners Investments Inc. grew its stake in shares of CVS Health by 19.6% during the second quarter. Value Partners Investments Inc. now owns 1,190,922 shares of the pharmacy operator’s stock valued at $70,336,000 after purchasing an additional 195,337 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors.

CVS Health Trading Down 0.2 %

NYSE:CVS opened at $59.85 on Monday. The business’s 50-day simple moving average is $59.36 and its 200-day simple moving average is $58.77. CVS Health Co. has a fifty-two week low of $52.71 and a fifty-two week high of $83.25. The stock has a market capitalization of $75.32 billion, a PE ratio of 15.19, a price-to-earnings-growth ratio of 1.02 and a beta of 0.55. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The business had revenue of $95.43 billion during the quarter, compared to analyst estimates of $92.72 billion. During the same quarter in the previous year, the business posted $2.21 EPS. CVS Health’s quarterly revenue was up 6.3% on a year-over-year basis. Sell-side analysts expect that CVS Health Co. will post 5.37 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Monday, October 21st were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Monday, October 21st. This represents a $2.66 annualized dividend and a dividend yield of 4.44%. CVS Health’s dividend payout ratio is currently 67.51%.

Analyst Ratings Changes

CVS has been the topic of several research reports. UBS Group upped their price objective on CVS Health from $60.00 to $62.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Truist Financial reaffirmed a “buy” rating and set a $67.00 price target (down previously from $76.00) on shares of CVS Health in a research note on Wednesday, November 20th. Royal Bank of Canada lowered their price objective on CVS Health from $68.00 to $58.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Barclays cut their target price on shares of CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th. Finally, TD Cowen boosted their price target on shares of CVS Health from $73.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and an average target price of $70.33.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.